-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Mayne Pharma announced that the US FDA has approved the company's Nextstellis (drospirenone and estrol compound tablets) to be marketed for the prevention of pregnancy.
At present, short-term contraceptives are mostly composed of estrogen and progesterone, and more than 99% of estrogen is ethinyl estradiol (EE).
Nextstellis is unique in that it uses estrogen, which can selectively bind to specific tissues in the body, while retaining the contraceptive effect, while reducing the possible side effects of estrogen.
▲The molecular structure of estrol (photo source: Edgar181, Public domain, via Wikimedia Commons)
The effectiveness and safety of Nextstellis are supported by clinical development projects involving multiple patient groups.
"The approval of Nextstellis provides women with a new option to maintain reproductive health and is an important milestone.
Reference materials:
[1] US FDA Approves NEXTSTELLIS®, New Oral Contraceptive.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.